527 related articles for article (PubMed ID: 30066131)
21. From fracture risk prediction to evaluating fracture patterns: recent advances in the epidemiology of osteoporosis.
Wright NC; Saag KG
Curr Rheumatol Rep; 2012 Jun; 14(3):205-11. PubMed ID: 22453874
[TBL] [Abstract][Full Text] [Related]
22. Disparities in osteoporosis treatments.
Liu Z; Weaver J; de Papp A; Li Z; Martin J; Allen K; Hui S; Imel EA
Osteoporos Int; 2016 Feb; 27(2):509-19. PubMed ID: 26216226
[TBL] [Abstract][Full Text] [Related]
23. Fracture Risk Assessment in Patients With Diabetes Mellitus.
Poiana C; Capatina C
J Clin Densitom; 2017; 20(3):432-443. PubMed ID: 28716499
[TBL] [Abstract][Full Text] [Related]
24. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Sato M; Ye W; Sugihara T; Isaka Y
BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
[TBL] [Abstract][Full Text] [Related]
25. Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy's fracture clinic screening program.
Beaton DE; Dyer S; Jiang D; Sujic R; Slater M; Sale JE; Bogoch ER;
Osteoporos Int; 2014 Jan; 25(1):289-96. PubMed ID: 23794044
[TBL] [Abstract][Full Text] [Related]
26. Bone health in type 1 diabetes.
Shah VN; Carpenter RD; Ferguson VL; Schwartz AV
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):231-236. PubMed ID: 29794498
[TBL] [Abstract][Full Text] [Related]
27. Treatment of bone fragility in patients with diabetes: antiresorptive versus anabolic?
Shah M; Appuswamy AV; Rao SD; Dhaliwal R
Curr Opin Endocrinol Diabetes Obes; 2021 Aug; 28(4):377-382. PubMed ID: 34010225
[TBL] [Abstract][Full Text] [Related]
28. Addition of a fracture risk assessment to a coordinator's role improved treatment rates within 6 months of screening in a fragility fracture screening program.
Beaton DE; Vidmar M; Pitzul KB; Sujic R; Rotondi NK; Bogoch ER; Sale JEM; Jain R; Weldon J
Osteoporos Int; 2017 Mar; 28(3):863-869. PubMed ID: 27770155
[TBL] [Abstract][Full Text] [Related]
29. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures.
Heilmeier U; Carpenter DR; Patsch JM; Harnish R; Joseph GB; Burghardt AJ; Baum T; Schwartz AV; Lang TF; Link TM
Osteoporos Int; 2015 Apr; 26(4):1283-93. PubMed ID: 25582311
[TBL] [Abstract][Full Text] [Related]
30. Drugs for the treatment of metabolic bone diseases.
Drake MT; Cremers S; Russell RG; Bilezikian JP
Br J Clin Pharmacol; 2019 Jun; 85(6):1049-1051. PubMed ID: 30950086
[No Abstract] [Full Text] [Related]
31. Research for correlation between heart rate variability parameters and bone mineral density in patients of type 2 diabetes mellitus.
Zhang Y; Bai J; Li L; Yang H; Yang Y; Lv H
J Endocrinol Invest; 2023 Jan; 46(1):79-88. PubMed ID: 35925468
[TBL] [Abstract][Full Text] [Related]
32. Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia.
Fernández-Ávila DG; Rincón-Riaño DN; Pinzón DF; Gutiérrez Dávila JM
Arch Osteoporos; 2019 Sep; 14(1):95. PubMed ID: 31486920
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and treatment of osteoporosis in older adults.
Diab DL; Watts NB
Endocrinol Metab Clin North Am; 2013 Jun; 42(2):305-17. PubMed ID: 23702403
[TBL] [Abstract][Full Text] [Related]
34. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options.
Rothman MS; Bessesen MT
Curr Osteoporos Rep; 2012 Dec; 10(4):270-7. PubMed ID: 23100110
[TBL] [Abstract][Full Text] [Related]
35. The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.
Chakhtoura M; Leslie WD; McClung M; Cheung AM; Fuleihan GE
Osteoporos Int; 2017 Jan; 28(1):127-137. PubMed ID: 27650643
[TBL] [Abstract][Full Text] [Related]
36. Diabetes and Osteoporosis: Part II, Clinical Management.
Schacter GI; Leslie WD
Endocrinol Metab Clin North Am; 2021 Jun; 50(2):287-297. PubMed ID: 34023044
[TBL] [Abstract][Full Text] [Related]
37. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
38. Bone, sweet bone--osteoporotic fractures in diabetes mellitus.
Hamann C; Kirschner S; Günther KP; Hofbauer LC
Nat Rev Endocrinol; 2012 Jan; 8(5):297-305. PubMed ID: 22249517
[TBL] [Abstract][Full Text] [Related]
39. Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice.
Shevroja E; Lamy O; Kohlmeier L; Koromani F; Rivadeneira F; Hans D
J Clin Densitom; 2017; 20(3):334-345. PubMed ID: 28734710
[TBL] [Abstract][Full Text] [Related]
40. [OSTEOPOROSIS AND DIABETES - IN WHICH WAY ARE THEY RELATED?].
Tell-Lebanon O; Rotman-Pikielny P
Harefuah; 2016 Nov; 155(11):697-701. PubMed ID: 28530076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
